Aproxi EZY Capsule

Aproxi EZY Capsule 125 mg+80 mg+80 mg, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aproxi EZY Capsule 125 mg+80 mg+80 mg is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aproxi EZY Capsule 125 mg+80 mg+80 mg has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).

Aproxi EZY Capsule 125 mg+80 mg+80 mg is a substance P/neurokinin 1 receptor antagonist used to treat nausea and vomiting caused by chemotherapy and surgery.

For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).

• Nausea and vomiting

Aproxi EZY Capsule 125 mg+80 mg+80 mg, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aproxi EZY Capsule 125 mg+80 mg+80 mg is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aproxi EZY Capsule 125 mg+80 mg+80 mg has little or no affinity for serotonin (5-HT₃), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).

Aproxi EZY Capsule 125 mg+80 mg+80 mg has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with Aproxi EZY Capsule 125 mg+80 mg+80 mg have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that Aproxi EZY Capsule 125 mg+80 mg+80 mg augments the antiemetic activity of the 5-HT₃-receptor antagonist ondansetron and the corticosteroid ethasone and inhibits both the acute and delayed phases of cisplatin induced emesis.

The mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.

• 70 L

Protein binding is reported to be >95%.

Aproxi EZY Capsule 125 mg+80 mg+80 mg is eliminated primarily by metabolism; aprepitant is not renally excreted. Aproxi EZY Capsule 125 mg+80 mg+80 mg is excreted in the milk of rats. It is not known whether this drug is excreted in human milk.

9-13 hours

• Apparent plasma cl=62-90 mL/min

• Take with or without food. The absorption is unaffected by food.

• Day 1: Aproxi EZY Capsule 125 mg+80 mg+80 mg 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): 24 mg 30 minutes before the start of chemotherapy.
• Day 2: Aproxi EZY Capsule 125 mg+80 mg+80 mg 80 mg orally, Dexamethasone 8 mg orally
• Day 3: Aproxi EZY Capsule 125 mg+80 mg+80 mg 80 mg orally, Dexamethasone 8 mg orally
• Day 4: Dexamethasone 8 mg orally

• Day 1: Aproxi EZY Capsule 125 mg+80 mg+80 mg 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): one 8 mg tablet 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later.
• Day 2: Aproxi EZY Capsule 125 mg+80 mg+80 mg 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day
• Day 3: Aproxi EZY Capsule 125 mg+80 mg+80 mg 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day.